Assembly Biosciences, Inc. V7B1.F Stock
Assembly Biosciences, Inc. Price Chart
Assembly Biosciences, Inc. V7B1.F Financial and Trading Overview
Assembly Biosciences, Inc. stock price | 0.95 EUR |
Previous Close | 0.96 EUR |
Open | 0.98 EUR |
Bid | 0.98 EUR x 200000 |
Ask | 1 EUR x 200000 |
Day's Range | 0.98 - 0.98 EUR |
52 Week Range | 0.73 - 2.35 EUR |
Volume | 940 EUR |
Avg. Volume | 1.99K EUR |
Market Cap | 50.92M EUR |
Beta (5Y Monthly) | 0.686267 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.71 EUR |
V7B1.F Valuation Measures
Enterprise Value | -17122022 EUR |
Trailing P/E | N/A |
Forward P/E | -0.4400901 |
PEG Ratio (5 yr expected) | -0.08 |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.7226331 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | 0.193 |
Trading Information
Assembly Biosciences, Inc. Stock Price History
Beta (5Y Monthly) | 0.686267 |
52-Week Change | -48.94% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.35 EUR |
52 Week Low | 0.73 EUR |
50-Day Moving Average | 0.91 EUR |
200-Day Moving Average | 1.33 EUR |
V7B1.F Share Statistics
Avg. Volume (3 month) | 1.99K EUR |
Avg. Daily Volume (10-Days) | 224 EUR |
Shares Outstanding | 52.12M |
Float | 51.04M |
Short Ratio | N/A |
% Held by Insiders | 1.31% |
% Held by Institutions | 27.51% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -45.46% |
Return on Equity (ttm) | -81.93% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -88912000 EUR |
Net Income Avi to Common (ttm) | -88951000 EUR |
Diluted EPS (ttm) | -1.62 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 73.02M EUR |
Total Cash Per Share (mrq) | 1.4 EUR |
Total Debt (mrq) | 2.63M EUR |
Total Debt/Equity (mrq) | 3.73 EUR |
Current Ratio (mrq) | 7.998 |
Book Value Per Share (mrq) | 1.352 |
Cash Flow Statement
Operating Cash Flow (ttm) | -80389000 EUR |
Levered Free Cash Flow (ttm) | -47527752 EUR |
Profile of Assembly Biosciences, Inc.
Country | Germany |
State | CA |
City | South San Francisco |
Address | 331 Oyster Point Boulevard |
ZIP | 94080 |
Phone | 833 509 4583 |
Website | https://www.assemblybio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 70 |
Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Q&A For Assembly Biosciences, Inc. Stock
What is a current V7B1.F stock price?
Assembly Biosciences, Inc. V7B1.F stock price today per share is 0.95 EUR.
How to purchase Assembly Biosciences, Inc. stock?
You can buy V7B1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Assembly Biosciences, Inc.?
The stock symbol or ticker of Assembly Biosciences, Inc. is V7B1.F.
Which industry does the Assembly Biosciences, Inc. company belong to?
The Assembly Biosciences, Inc. industry is Biotechnology.
How many shares does Assembly Biosciences, Inc. have in circulation?
The max supply of Assembly Biosciences, Inc. shares is 5.69M.
What is Assembly Biosciences, Inc. Price to Earnings Ratio (PE Ratio)?
Assembly Biosciences, Inc. PE Ratio is 0.00000000 now.
What was Assembly Biosciences, Inc. earnings per share over the trailing 12 months (TTM)?
Assembly Biosciences, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Assembly Biosciences, Inc. company belong to?
The Assembly Biosciences, Inc. sector is Healthcare.